Vaccinare
I vantaggi dei vaccini combinati
ADVANTAGES OF COMBINED VACCINES
GIORGIO BARTOLOZZI
Dipartimento di Pediatria, Università di Firenze
Settembre 1998 - pagg. 461 -463
Abstract
The introduction of combined vaccines can
significantly improve immunization coverage
and reduce costs. The Author reviews
the state-of-the-art of combined vaccines.
At present, given its insufficient immunogenicity,
the combined DTP-Hib vaccine cannot
be recommended. Immunogenicity of
combined DTPa-polio vaccine and of DTPa-
HBV vaccine are, on the contrary, quite satisfactory.
The latter can be used with all
the current immunization schedules and
appears particularly advantageous.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Bartolozzi G: Troppi vaccini? Medico e
Bambino 11, 459-69, 1992.
2. Bartolozzi G: Vaccini combinati per nuove vaccinazioni. Vaccinazione 2000 6, n.31, 1-3, 1994.
3. Bartolozzi G, Longo G: Thimerosal, “allergia” all’aspirina e vaccini. Medico e Bambino 15, 115-6, 1996.
4. Centers for Disease Control and Prevention (CDC): FDA approval of a Haemophilus influenzae b conjugate vaccine combined by reconstruction with an acellular pertussis vaccine. MMWR 45, 993-5, 1996.
5. Dagan R, Igbaria K, Piglansky L, et al: Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis 16, 113-21, 1997.
6. Diez-Delgado J, Dal-Ré R, Lorente M, et al: Hepatitis B component not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 15, 1418-22, 1997.
7. Edwards ME, Decker MD: Combination vaccines consisting of acellular pertussis vaccines. Pediatr Infect Dis J 16, S97-102, 1997.
8. Eskola J, Olander RM, Hovi T, et al: Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348, 1688- 92, 1996.
9. Giammanco G, Moiraghi A, Zotti C, et al: Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Vaccine 16, 722-6, 1998.
10. Usonis V, Bakasenas V, Willems P, Clemens R: Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs. Vaccine 15, 1680-6, 1997.
2. Bartolozzi G: Vaccini combinati per nuove vaccinazioni. Vaccinazione 2000 6, n.31, 1-3, 1994.
3. Bartolozzi G, Longo G: Thimerosal, “allergia” all’aspirina e vaccini. Medico e Bambino 15, 115-6, 1996.
4. Centers for Disease Control and Prevention (CDC): FDA approval of a Haemophilus influenzae b conjugate vaccine combined by reconstruction with an acellular pertussis vaccine. MMWR 45, 993-5, 1996.
5. Dagan R, Igbaria K, Piglansky L, et al: Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis 16, 113-21, 1997.
6. Diez-Delgado J, Dal-Ré R, Lorente M, et al: Hepatitis B component not interfere with the immune response to diphtheria, tetanus and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 15, 1418-22, 1997.
7. Edwards ME, Decker MD: Combination vaccines consisting of acellular pertussis vaccines. Pediatr Infect Dis J 16, S97-102, 1997.
8. Eskola J, Olander RM, Hovi T, et al: Randomized trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348, 1688- 92, 1996.
9. Giammanco G, Moiraghi A, Zotti C, et al: Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Vaccine 16, 722-6, 1998.
10. Usonis V, Bakasenas V, Willems P, Clemens R: Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs. Vaccine 15, 1680-6, 1997.